OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder

References

• Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J. Atten. Disord.9(2), 384–391 (2005).
   PubMedGoogle Scholar
• Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet366(9481), 237–248 (2005).
   PubMed Web of Science ®Google Scholar
• Adler LA, Chua HC. Management of ADHD in adults. J. Clin. Psychiatry63(Suppl. 12), 29–35 (2002).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) . Text Revision. Washington DA (Eds). The American Psychiatric Association, WA, USA (2000).
   Google Scholar
• Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol. Med.35(6), 817–827 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry163(4), 716–723 (2006).
   PubMed Web of Science ®Google Scholar
• Lamberg L. ADHD often undiagnosed in adults: appropriate treatment may benefit work, family, social life. JAMA290(12), 1565–1567 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr. Psychiatry37(6), 393–401 (1996).
   PubMed Web of Science ®Google Scholar
• Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry63(Suppl. 12), 10–15 (2002).
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. Med. Gen. Med.8(3), 12 (2006).
   PubMedGoogle Scholar
• Biederman J, Petty CR, Fried R et al. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J. Clin. Psychiatry69(8), 1217–1222 (2008).
   PubMed Web of Science ®Google Scholar
• Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry65(Suppl. 3), 3–7 (2004).
   PubMed Web of Science ®Google Scholar
• Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr. Clin. North Am.27(2), 187–201 (2004).
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. NICE Clinical Guideline 72. Attention deficit hyperacitivity disorder. Diagnosis and management of ADHD in children, young people and adults (2008).
   Google Scholar
• Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J. Atten. Disord.5(4), 189–202 (2002).
   PubMedGoogle Scholar
• Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol.24(1), 24–29 (2004).
   PubMed Web of Science ®Google Scholar
• Stein MA, Blondis TA, Schnitzler ER et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics98(4 Pt 1), 748–756 (1996).
   PubMed Web of Science ®Google Scholar
• Pelham WE Jr, McBurnett K, Harper GW et al. Methylphenidate and baseball playing in ADHD children: who’s on first? J. Consult. Clin. Psychol.58(1), 130–133 (1990).
   PubMed Web of Science ®Google Scholar
• Darredeau C, Barrett SP, Jardin B, Pihl RO. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum. Psychopharmacol.22(8), 529–536 (2007).
   PubMed Web of Science ®Google Scholar
• Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. NICE guidance on ADHD. Diversion and abuse of methylphenidate in light of new guidance. BMJ337, A2287 (2008).
   PubMedGoogle Scholar
• Wilens TE, Adler LA, Adams J et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry47(1), 21–31 (2008).
   PubMed Web of Science ®Google Scholar
• Kaiser NM, Hoza B, Hurt EA. Multimodal treatment for childhood attention-deficit/hyperactivity disorder. Expert Rev. Neurother.8(10), 1573–1583 (2008).
   PubMedGoogle Scholar
• Rollini M, Baud P. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults. Rev. Med. Suisse4(165), 1638–1643 (2008).
   PubMedGoogle Scholar
• Benner-Davis S, Heaton PC. Attention deficit and hyperactivity disorder: controversies of diagnosis and safety of pharmacological and nonpharmacological treatment. Curr. Drug Saf.2(1), 33–42 (2007).
   PubMedGoogle Scholar
• Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed8(4), 4 (2006).
   PubMedGoogle Scholar
• Zabik JE, Levine RM, Maickel RP. Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity. Pharmacol. Biochem. Behav.8(4), 429–435 (1978).
   PubMed Web of Science ®Google Scholar
• Swanson J, Gupta S, Lam A et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch. Gen. Psychiatry60(2), 204–211 (2003).
   PubMed Web of Science ®Google Scholar
• Patrick KS, González MA, Straughn AB, Markowitz JS. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Drug Deliv.2(1), 121–143 (2005).
   PubMedGoogle Scholar
• Faraj BA, Israili ZH, Perel JM et al. Metabolism and disposition of methylphenidate-14C: studies in man and animals. J. Pharmacol. Exp. Ther.191(3), 535–547 (1974).
   PubMed Web of Science ®Google Scholar
• Chan YM, Soldin SJ, Swanson JM, Deber CM, Thiessen JJ, Macleod S. Gas chromatographic/mass spectrometric analysis of methylphenidate (ritalin) in serum. Clin. Biochem.13(6), 266–272 (1980).
   PubMed Web of Science ®Google Scholar
• Patrick KS, Ellington KR, Breese GR. Distribution of methylphenidate and p-hydroxymethylphenidate in rats. J. Pharmacol. Exp. Ther.231(1), 61–65 (1984).
   PubMed Web of Science ®Google Scholar
• Modi NB, Wang B, Hu WT, Gupta SK. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm. Drug Dispos.21(1), 23–31 (2000).
   PubMed Web of Science ®Google Scholar
• Rochdi M, González MA, Dirksen SJ. Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule. Int. J. Clin. Pharmacol. Ther.42(5), 285–292 (2004).
   PubMed Web of Science ®Google Scholar
• Modi NB, Wang B, Noveck RJ, Gupta SK. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J. Clin. Pharmacol.40(10), 1141–1149 (2000).
   PubMed Web of Science ®Google Scholar
• Pelham WE, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics107(6), E105 (2001).
   PubMedGoogle Scholar
• Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci. Biobehav. Rev.27(7), 615–621 (2003).
   PubMed Web of Science ®Google Scholar
• Auiler JF, Liu K, Lynch JM, Gelotte CK. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall Food Evaluation (CAFE) study. Curr. Med. Res. Opin.18(5), 311–316 (2002).
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Straughn AB, Patrick KS et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin. Pharmacokinet.42(4), 393–401 (2003).
   PubMed Web of Science ®Google Scholar
• Gonz ález MA, Pentikis HS, Anderl N et al. Methylphenidate bioavailability from two extended-release formulations. Int. J. Clin. Pharmacol. Ther.40(4), 175–184 (2002).
   PubMedGoogle Scholar
• Greenhill LL. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr. Clin. North Am. (1), 1–27 (1992).
   PubMedGoogle Scholar
• Gatley SJ, Volkow ND, Gifford AN et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl.)146(1), 93–100 (1999).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry155(10), 1325–1331 (1998).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord.6(Suppl. 1), S31–S43 (2002).
   PubMedGoogle Scholar
• Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphenidate. J. Pharmacol. Exp. Ther.241(1), 152–158 (1987).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS et al. “Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse44(3), 175–180 (2002).
   PubMed Web of Science ®Google Scholar
• Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res.94(1), 127–152 (1998).
   PubMed Web of Science ®Google Scholar
• Seeman P, Madras B. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav. Brain Res.130(1–2), 79–83 (2002).
   PubMed Web of Science ®Google Scholar
• Wachtel H, Kandel ER. A direct synaptic connection mediating both excitation and inhibition. Science158(805), 1206–1208 (1967).
   PubMedGoogle Scholar
• Chuang TT, Iacovelli L, Sallese M, De Blasi A. G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications. Trends Pharmacol. Sci.17(11), 416–421 (1996).
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Surman C et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry.59(9), 829–835 (2006).
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick EO, Surman C et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry7, 49 (2007).
   PubMed Web of Science ®Google Scholar
• Medori R, Ramos-Quiroga JA, Casas M et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry63(10), 981–989 (2008).
   PubMed Web of Science ®Google Scholar
• Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J. Clin. Psychiatry68(1), 93–101 (2007).
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Spencer T et al. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr.11(5), 390–396 (2006).
   PubMed Web of Science ®Google Scholar
• Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr. Med. Res. Opin.22(12), 2557–2566 (2006).
   PubMed Web of Science ®Google Scholar
• Ramos-Quiroga JA, Bosch R, Castells X et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs22(7), 603–611 (2008).
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry57(5), 456–463 (2005).
   PubMed Web of Science ®Google Scholar
• Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur. Arch. Psychiatry Clin. Neurosci.256(Suppl. 1), I26–I31 (2006).
   PubMed Web of Science ®Google Scholar
• Ramos-Quiroga JA, Bosch R, Casas M. El TDAH en la edad adulta. In: El Alumno con TDAH. Guía Pràctica Para Educadores. Mena B, Nicolau R, Salat L, Tort P, Romero B (Eds). Ediciones Mayo, Barcelona, Spain 43–46 (2006).
   Google Scholar
• Ramos-Quiroga JA, Bosch-Munso R, Castells-Cervello X, Nogueira-Morais M, Garcia-Gimenez E, Casas-Brugue M. Attention deficit hyperactivity disorder in adults: a clinical and therapeutic characterization. Rev. Neurol.42, 600–606 (2006).
   PubMedGoogle Scholar
• Bekker EM, Overtoom CC, Kooij JJ, Buitelaar JK, Verbaten MN, Kenemans JL. Disentangling deficits in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry62(10), 1129–1136 (2005).
   PubMed Web of Science ®Google Scholar
• Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry54(12), 1465–1468 (2003).
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Schoedel KA, Schuller R et al. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J. Clin. Pharmacol.47(12), 1476–1488 (2007).
   PubMed Web of Science ®Google Scholar
• Bayes M, Ramos JA, Cormand B et al. Large-scale genotyping in research into autism spectrum disorders and attention deficit hyperactivity disorder. Rev. Neurol.40(Suppl. 1), S187–S190 (2005).
   PubMedGoogle Scholar
• Ribases M, Hervas A, Ramos-Quiroga JA et al. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder: contribution of ciliary neurotrophic factor receptors, neurotrophic factor receptor 3, and neurotrophic tyrosine kinase receptor 2. Biol. Psychiatry63(10), 935–945 (2008).
   PubMed Web of Science ®Google Scholar
• Ramos-Quiroga JA, Ribases-Haro M, Bosch-Munso R, Cormand-Rifa B, Casas M. Genetic advances in attention deficit hyperactivity disorder. Rev. Neurol.44(Suppl. 3), S51–S52 (2007).
   PubMedGoogle Scholar
• Castellanos FX, Lee PP, Sharp W et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA288, 1740–1748 (2002).
   PubMed Web of Science ®Google Scholar
• Seidman LJ, Valera EM, Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biol. Psychiatry57(11), 1263–1272 (2005).
   PubMed Web of Science ®Google Scholar
• Bush G, Frazier JA, Rauch SL et al. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol. Psychiatry.45, 1542–1552 (1999).
   PubMed Web of Science ®Google Scholar
• Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol. Psychiatry.57(11), 1273–1284 (2005).
   PubMed Web of Science ®Google Scholar
• Valera EM, Faraone SV, Biederman J, Poldrack RA, Seidman LJ. Functional neuroanatomy of working memory in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry57(5), 439–447 (2005).
   PubMed Web of Science ®Google Scholar
• Rommelse NN, Altink ME, Martin NC et al. Neuropsychological measures probably facilitate heritability research of ADHD. Arch. Clin. Neuropsychol.23(5), 579–591 (2008).
   PubMed Web of Science ®Google Scholar
• Wodka EL, Mostofsky SH, Prahme C et al. Process examination of executive function in ADHD: sex and subtype effects. Clin. Neuropsychol.22(5), 826–841 (2008).
   PubMed Web of Science ®Google Scholar
• Dresel S, Krause J, Krause KH et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur. J. Nucl. Med.27, 1518–1524 (2000).
   PubMedGoogle Scholar
• Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett.285, 107–110 (2000).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry57, 1410–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Ribases M, Ramos-Quiroga JA, Hervas A et al. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol. Psychiatry.14(1), 71–85 (2009).
   PubMed Web of Science ®Google Scholar